Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -1,1 (-1,5)
- Earnings per share* SEK -0.06 (-0.10)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.
Summary of the nine-month period (2021-07-01 - 2021-12-31)- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -3,2 (-4,6)
- Earnings per share* SEK -0.20 (-0.31)
- Cash and cash equivalents at the end of the period amounted to MSEK 38,9 (3,5)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 16,225,200. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.
CEO's comment
The clinical myeloma study with the Company's drug candidate OsteoDex, which was financed via a rights issue in December 2021 that provided the company with SEK 37 million after issue costs, is proceeding according to plan. The work is in progress with a complete application to the Medical Products Agency in Uppsala. The application includes study protocols, IB (Investigators Brochure), Investigational Medicinal Product Dossier (IMPD) in updated format.
Our previous preclinical studies regarding the effect of OsteoDex on different myeloma cell cultures clearly show a strong tumor cell killing effect. Even compared to Melfalan, which is a proven standard preparation for the treatment of multiple myeloma (MM), the effect of OsteoDex is strikingly strong. Given the similarity in the skeletal disease process between MM and mCRPC and existing clinical experience, we have reason to be optimistic about the MM study's conditions to result in "proof of concept".
In April, the company convened an extraordinary general meeting on May 11, where Andreas Segerros is proposed as a new board member. Andreas Segerros has long and solid experience with executive positions in the international pharmaceutical industry, in Europe, the USA and Japan. Andreas Segerros will be a key person in the Company's continued development, this in perspective of his previous experience and associated network.
Anders R Holmberg
CEO
Contact
Anders Holmberg, CEO, +46 73 324 27 82
Gösta Lundgren, CFO, +46 70 710 47 88
This information is such information that DexTech Medical AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on April 29, 2022 through the care of the above contact persons.
DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail existing drugs. DexTech's goal is to outlicense the respective drug candidate no later than after the completion of a phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.